ViewRay competitors

Experienced public company Chief Executive Officer and board member in small and mid cap medical device/technology companies with a demonstrated history of driving shareholder value. Primary career path experience in sales management and commercial operations, strategic marketing and business development. Broad range of product/market experiences covering the full spectrum from FDA Class 3 implantable devices to multi-million dollar complex medical equipment

Joined the Company as President and Chief Executive Officer in January 2012. Prior to joining Aehr, Mr. Erickson served as Corporate Officer and Senior Vice President & General Manager of Verigy’s memory test business. Prior to that, Mr. Erickson was Vice President of Marketing and Sales for Agilent Technologies’ Semiconductor Memory Test products. He has over 23 years of executive and general management, operations,marketing, sales, and R&D program management experience dating back to the late 1980s, when he began his career in semiconductor test with Hewlett-Packard’s Automated Test Group. He received a B.S. in Electrical Engineering from Arizona State University.

Mary Puma is a Chairman and CEO at AXCELIS TECHNOLOGIES INC.

A broadly experienced leader with a record of holding key management responsibilities within a market leading provider of semiconductor production equipment and services. Directly responsible for key business innovations and execution in product development, product marketing and product management, enabling growth from ~$100M to over $500M globally. Proven ability in project development, implementation, and management of advanced technology products. A key contributor and highly respected with eighteen years of high technology industry experience. Specialties: Managing technically complex product development teams.

Gilles Martin is the executive chairman of Eurofins Scientific, a Luxembourg-based laboratory services company listed on the French stock exchange. Martin, who founded the original lab in 1987, owns an estimated 25% of the company through the family's holding company Analytical Bioventures.